AstraZeneca is a U.K.-based global biopharmaceutical company operating in the Healthcare sector. Established in the late 1990s and headquartered in Cambridge, United Kingdom, the company focuses on the research, development, and commercialization of prescription medicines.

AstraZeneca concentrates its portfolio on several key therapeutic areas:

• Oncology: Treatments for multiple types of cancer.

• Cardiovascular, Renal and Metabolism: Therapies addressing heart disease and related conditions.

• Respiratory and Immunology: Medicines for asthma, COPD, and inflammatory diseases.

• Infectious Diseases: Antiviral and vaccine-related solutions.

• Neuroscience: Research and treatments for disorders affecting the central nervous system.

The company operates in more than 100 countries and maintains a broad global manufacturing and commercial footprint. It also owns Alexion Pharmaceuticals, a subsidiary focused on rare diseases and specialty therapies.

AstraZeneca supports its innovation pipeline through a network of research and development centers across Europe, North America, and Asia. Its shares trade on the London Stock Exchange (LSE) under AZN and in the United States as American Depositary Receipts (ADRs) under the ticker AZN on the Nasdaq.

History and Development

AstraZeneca was formed in the late 1990s through the merger of Sweden-based Astra AB and the U.K.-based Zeneca Group, creating a multinational pharmaceutical company with a diversified research portfolio.

Following the merger, the company expanded globally, strengthening its presence in key markets and investing in advanced research infrastructure.

Throughout the 2000s and 2010s, AstraZeneca pursued strategic acquisitions and partnerships to reinforce its pipeline in oncology, biologics, and rare diseases. These transactions broadened its therapeutic focus and increased its exposure to high-growth specialty areas.

In recent years, the company has emphasized innovation in oncology and immunology, as well as biologic medicines and rare disease treatments through its subsidiary operations.

Beginning in the early 2020s, AstraZeneca gained additional global visibility through vaccine development and large-scale international distribution efforts. The company continues to invest heavily in research, aiming to expand its portfolio of advanced therapies and maintain its position among the world’s leading pharmaceutical manufacturers.

Additional Information

AstraZeneca PLC (United States) is listed on the Nasdaq and has a market capitalization of $246.86 billion, with shareholders equity totaling $50.37 billion.

The company employs approximately 74.800 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, AstraZeneca PLC reported $76.56 billion in revenue, generating net income of $12.98 billion.

Key financial metrics include a P/E ratio of 19.02, a price-to-book (P/B) ratio of 4.90, and a trailing twelve-month dividend yield of 2.03%.

The company trades under the ticker AZN.